The Polish adaptation of the CAMbridge Pulmonary Hypertension Outcome Review (CAMPHOR).
CAMPHOR
adaptation
patient reported outcome
pulmonary hypertension
quality of life
Journal
Cardiology journal
ISSN: 1898-018X
Titre abrégé: Cardiol J
Pays: Poland
ID NLM: 101392712
Informations de publication
Date de publication:
2020
2020
Historique:
received:
21
02
2018
accepted:
02
09
2018
revised:
09
08
2018
pubmed:
20
10
2018
medline:
18
8
2021
entrez:
20
10
2018
Statut:
ppublish
Résumé
Pulmonary hypertension (PH) results in severely impaired quality of life (QoL) in people with this condition. The CAMbridge Pulmonary Hypertension Outcome Review (CAMPHOR) is the only questionnaire providing a disease-specific measurement of symptoms, functioning and QoL in PH patients. It has already been adapted for use in several countries. The aim of this study was to adapt and validate CAMPHOR for the Polish-speaking population. Two panels (bilingual and lay) were conducted to translate CAMPHOR into Polish. This new version was then tested by cognitive debriefing interviews with 15 patients. Finally, a postal validation survey was conducted with 56 patients on two occasions 2 weeks apart to assess its psychometric properties. No problems were experienced in producing a Polish translation of CAMPHOR. Interviewees responded well to the Polish CAMPHOR, finding it relevant, comprehensible and easy to complete. For all three CAMPHOR scales (Symptoms, Activity, QoL), The Cronbach alpha coefficients were above 0.8 at both time points, indicating high internal consistency. Test-retest reliability for the three scales achieved a value above 0.80. Predicted correlations with the Nottingham Health Profile provided evidence of the construct validity of CAMPHOR scales. The Polish CAMPHOR could distinguish between patients who differed according to their perceived general health and perceived disease severity. No significant differences in scores were found between participants grouped by gender or age. The Polish version of CAMPHOR demonstrated good psychometric properties and is recommended for use in clinical practice.
Sections du résumé
BACKGROUND
Pulmonary hypertension (PH) results in severely impaired quality of life (QoL) in people with this condition. The CAMbridge Pulmonary Hypertension Outcome Review (CAMPHOR) is the only questionnaire providing a disease-specific measurement of symptoms, functioning and QoL in PH patients. It has already been adapted for use in several countries. The aim of this study was to adapt and validate CAMPHOR for the Polish-speaking population.
METHODS
Two panels (bilingual and lay) were conducted to translate CAMPHOR into Polish. This new version was then tested by cognitive debriefing interviews with 15 patients. Finally, a postal validation survey was conducted with 56 patients on two occasions 2 weeks apart to assess its psychometric properties.
RESULTS
No problems were experienced in producing a Polish translation of CAMPHOR. Interviewees responded well to the Polish CAMPHOR, finding it relevant, comprehensible and easy to complete. For all three CAMPHOR scales (Symptoms, Activity, QoL), The Cronbach alpha coefficients were above 0.8 at both time points, indicating high internal consistency. Test-retest reliability for the three scales achieved a value above 0.80. Predicted correlations with the Nottingham Health Profile provided evidence of the construct validity of CAMPHOR scales. The Polish CAMPHOR could distinguish between patients who differed according to their perceived general health and perceived disease severity. No significant differences in scores were found between participants grouped by gender or age.
CONCLUSIONS
The Polish version of CAMPHOR demonstrated good psychometric properties and is recommended for use in clinical practice.
Identifiants
pubmed: 30338844
pii: VM/OJS/J/57429
doi: 10.5603/CJ.a2018.0119
pmc: PMC8078996
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
608-615Références
Qual Life Res. 2006 Feb;15(1):103-15
pubmed: 16411035
Eur Respir J. 2011 Sep;38(3):608-16
pubmed: 21273391
J R Coll Gen Pract. 1985 Apr;35(273):185-8
pubmed: 3989783
Value Health. 2004 Sep-Oct;7 Suppl 1:S4-8
pubmed: 15367236
Health Policy. 1992 Oct;22(3):307-19
pubmed: 10122730
Health Qual Life Outcomes. 2016 Jul 26;14(1):110
pubmed: 27460644
Neth Heart J. 2016 Jun;24(6):417-424
pubmed: 27197970
Am J Hosp Palliat Care. 2016 Apr;33(3):214-21
pubmed: 25294227
N Engl J Med. 2002 Aug 1;347(5):322-9
pubmed: 12151469
J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S97-S107
pubmed: 19555863
Am J Respir Crit Care Med. 2002 Mar 15;165(6):800-4
pubmed: 11897647
Value Health. 2010 Jun-Jul;13(4):424-30
pubmed: 20070642
J Am Coll Cardiol. 2008 Dec 16;52(25):2127-34
pubmed: 19095129
Health Qual Life Outcomes. 2012 Sep 13;10:110
pubmed: 22971041
Can Respir J. 2008 Mar;15(2):77-83
pubmed: 18354747
N Engl J Med. 1996 Feb 1;334(5):296-301
pubmed: 8532025
Eur Heart J. 2016 Jan 1;37(1):67-119
pubmed: 26320113
Circulation. 2008 Jun 10;117(23):3010-9
pubmed: 18506008
Scand J Public Health. 2012 Dec;40(8):777-83
pubmed: 23117210
Respirology. 2011 Nov;16(8):1235-40
pubmed: 21810146
Eur Respir J. 2006 Oct;28(4):808-15
pubmed: 16707511
Chest. 2009 Jan;135(1):137-142
pubmed: 18812447
Rev Esp Cardiol (Engl Ed). 2017 Jun;70(6):467-473
pubmed: 27989660
J Heart Lung Transplant. 2008 Jan;27(1):124-30
pubmed: 18187098
Circulation. 2009 Jun 9;119(22):2894-903
pubmed: 19470885
Health Policy. 1991 Sep;19(1):33-44
pubmed: 10117390
Ann Intern Med. 2008 Oct 21;149(8):521-30
pubmed: 18936500
Eur Respir J. 2008 Dec;32(6):1513-9
pubmed: 18768576
Health Qual Life Outcomes. 2011 Aug 02;9:60
pubmed: 21810234
J Am Coll Cardiol. 2010 May 4;55(18):1915-22
pubmed: 20430262